Prestige Consumer Healthcare Inc
NYSE:PBH

Watchlist Manager
Prestige Consumer Healthcare Inc Logo
Prestige Consumer Healthcare Inc
NYSE:PBH
Watchlist
Price: 80.94 USD -1.44% Market Closed
Market Cap: 4B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PBH stock under the Base Case scenario is hidden USD. Compared to the current market price of 80.94 USD, Prestige Consumer Healthcare Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PBH Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
4
vs Industry
32
Median 3Y
2.8
Median 5Y
2.7
Industry
2.3
Forward
3.5
More Details
18.8
P/E
P/E
Price to Earnings
18.8
vs History
4
vs Industry
24
Median 3Y
14.6
Median 5Y
14.1
Industry
19.8
Forward
17.8
More Details
15.6
P/OCF
P/OCF
Price to OCF
15.6
vs History
4
vs Industry
26
Median 3Y
13.2
Median 5Y
12.3
Industry
14.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
19
Median 3Y
-88
Median 5Y
-21.1
Industry
22.2
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
4
vs Industry
32
Median 3Y
2
Median 5Y
1.9
Industry
1.9
More Details
4.4
EV/S
EV/S
Enterprise Value to Sales
4.4
vs History
6
vs Industry
26
Median 3Y
4
Median 5Y
3.9
Industry
2.4
Forward
4.3
More Details
8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8
vs History
4
vs Industry
25
Median 3Y
7.2
Median 5Y
7
Industry
4.7
More Details
13.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.7
vs History
19
vs Industry
26
Median 3Y
12.6
Median 5Y
12.4
Industry
12
Forward
13.2
More Details
15
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15
vs History
4
vs Industry
27
Median 3Y
12.9
Median 5Y
12.5
Industry
14.9
Forward
14.3
More Details
19.3
EV/OCF
EV/OCF
Enterprise Value to OCF
19.3
vs History
7
vs Industry
22
Median 3Y
18.4
Median 5Y
17.7
Industry
13.3
More Details
19.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19.9
vs History
11
vs Industry
22
Median 3Y
19.1
Median 5Y
18.5
Industry
17.2
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
4
vs Industry
42
Median 3Y
1.3
Median 5Y
1.3
Industry
1.7
More Details

Multiples Across Competitors

PBH Competitors Multiples
Prestige Consumer Healthcare Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Prestige Consumer Healthcare Inc
NYSE:PBH
4B USD 3.6 18.8 13.7 15
US
Eli Lilly and Co
NYSE:LLY
694.1B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.4B USD 4.2 26.3 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.1B CHF 4.3 18.7 11.3 14.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 3.9 29.9 126 192.4
US
Merck & Co Inc
NYSE:MRK
193.6B USD 3 11.3 7.7 9.1
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
112.8B EUR 2.5 19.6 8.6 12.6
P/E Multiple
Earnings Growth PEG
US
Prestige Consumer Healthcare Inc
NYSE:PBH
Average P/E: 25.2
18.8
6%
3.1
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
17.6
16%
1.1
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
29.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.6
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Prestige Consumer Healthcare Inc
NYSE:PBH
Average EV/EBITDA: 395.1
13.7
2%
6.9
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126
9%
14
US
Merck & Co Inc
NYSE:MRK
7.7
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.6
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Prestige Consumer Healthcare Inc
NYSE:PBH
Average EV/EBIT: 1 698.3
15
2%
7.5
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.6
14%
0.9

See Also

Summary
PBH intrinsic value, competitors valuation, and company profile.
DCF Valuation
PBH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PBH stock valuation using valuation multiples.
Wall Street Estimates
PBH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PBH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.